<?xml version="1.0" encoding="UTF-8"?>
<p id="p0140">The points in favour of the study:
 <list list-type="simple" id="l0020">
  <list-item id="li0050">
   <label>1.</label>
   <p id="p0145">Previous studies proving the effectiveness of PVP-I against MERS and SARS CoV</p>
  </list-item>
  <list-item id="li0055">
   <label>2.</label>
   <p id="p0150">The structural similarity of SARS CoV, SARS CoV 2 and MERS</p>
  </list-item>
  <list-item id="li0060">
   <label>3.</label>
   <p id="p0155">0.5% PVP-I is easy to prepare and is inexpensive</p>
  </list-item>
  <list-item id="li0065">
   <label>4.</label>
   <p id="p0160">PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally</p>
  </list-item>
  <list-item id="li0070">
   <label>5.</label>
   <p id="p0165">It is easy to dispense to patients and to health care workers</p>
  </list-item>
  <list-item id="li0075">
   <label>6.</label>
   <p id="p0170">No reported allergies</p>
  </list-item>
  <list-item id="li0080">
   <label>7.</label>
   <p id="p0175">Though not proved, it probably reduces the viral titres of SARS CoV 2</p>
  </list-item>
 </list>
</p>
